Journal of Experimental and Clinical SurgeryJournal of Experimental and Clinical Surgery2070-478X2409-143XVoronezh State Medical University151710.18499/2070-478X-2021-14-4-316-324UnknownEpigenetic Markers of Colorectal Cancer: Clinical Data AnalysisBagryantsevMaxim Vladimirovich<p>PhD</p>maks-bagryancev@mail.ruhttps://orcid.org/0000-0003-2230-9431SamoylenkoVyacheslav Mikhailovich<p>Professor, MD</p>lesamoylenko@gmail.ruhttps://orcid.org/0000-0002-5906-1399RyabkovMaxim Georgievich<p>Professor, MD</p>maxim-ryabkov@yandex.ruhttps://orcid.org/0000-0002-9555-190XBazaevAndrey Vladimirovich<p>Head of the Department of Surgery, professor, MD</p>official@semashko.nnov.ruhttps://orcid.org/0000-0001-9690-4191DesortsevIlya Lvovich<p>Head of the Proctology Department, PhD</p>dezortsev-il@yandex.ruhttps://orcid.org/0000-0003-3855-8686BunovaSvetlana Sergeevna<p>professor of the Department of Family Medicine, MD</p>ssbunova@mail.ruhttps://orcid.org/0000-0001-8430-6215BatanovMikhail Andreevich<p>residency</p>mihailbatanov69@mail.ruhttps://orcid.org/0000-0002-9663-1856KiselevaElena Borisovna<p>Researcher at the Laboratory of Optical Coherence Tomography, PhD.</p>kiseleva84@gmail.comhttps://orcid.org/0000-0003-4769-417XFederal State Budgetary Educational Institution of Higher Education «Privolzhsky» Research Medical University» of the Ministry of Health of the Russian FederationFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)State Budgetary Healthcare Institution of Nizhny Novgorod Region «Regional Clinic Hospital named after N.A. SemashkoFederal State Autonomous Educational Institution of Higher Education «Belgorod National Research University»1712202114431632403072021Copyright © 2021, Bagryantsev M.V., Samoylenko V.M., Ryabkov M.G., Bazaev A.V., Desortsev I.L., Bunova S.S., Batanov M.A., Kiseleva E.B.2021<p><strong>The aim of the study </strong>was to systematize the results of clinical application of epigenetic biomarkers "microRNA" and "DNA methylation" in early diagnosis and prognosis in patients with colorectal cancer.</p>
<p><strong>Material and methods.</strong> Data review was conducted by the keywords "colorectal cancer" with "miRNA" or "methylation" in PubMed, Cochrane Library, ScienceDirect, ELECTRONIC LIBRARY and was limited by the period 2016-2021. In addition, a manual search for articles in peer-reviewed journals was performed. Exclusion criteria were: description of separate clinical cases; books and documents; experimental oncology in laboratory animals, comparison of therapeutic results of patients receiving chemotherapy. Out of 139 initially identified, 37 sources were included in the final analysis, of which 20 meta-analyzes, 1 randomized clinical trial, 14 systematic reviews and 2 practical guidelines.</p>
<p><strong>Results. </strong>Based on the analysis of clinical data, it has been established that the optimal environment for miR isolation for early diagnosis of colorectal cancer is the intestinal wall, furthermore, miR-139 has a proven diagnostic value. At the later stages of tumor development, fecal miRs, namely miR-21, can also be used as a screening method. MiR-181a, miR-181b, miR-20a, miR-10b and miR-145 are highly sensitive predictors of overall survival in colorectal cancer patients. They can potentially be considered as prognostic biomarkers and as decisions when administering adjuvant chemotherapy. miR21, miR106a, miR143, miR 150 and miR215 are most commonly used in clinical practice to determine the prognosis of treatment. Tumor and paratumor tissues can also be differentiated from the normal colon tissue in a healthy person by methylation of the SFRP2, SFRP1, TFPI2, BMP3, NDRG4, SPG20, BMP3 and NDRG4, SFRP1, 2, 4, 5, hMLH1 and RASSF1A genes. The analysis of methylated SEPT9 genes is the most informative of them: an increased weight of the mitylated SEPT9 gene directly correlates with progression and low tumor differentiation in patients with colorectal cancer.</p>
<p><strong>Conclusion</strong>. Literature data confirm that changes in the concentration of microRNA and methylated DNA in the environments of the human body correlate with the risk of oncogenesis, progression and invasion of colorectal cancer. It is reasonable to use a diagnostic algorithm differentiated by the analyzed tissues (blood, intestinal tissue, feces, urine), the expected stage of tumor development, diagnostic tasks (screening, survival prognosis) for the effective use of epigenetic markers of colorectal cancer in the clinical practice.</p>colorectal cancerepigeneticsmicroRNADNA methylationколоректальный ракэпигенетикамикроРНКметилирование ДНК[1. Fedyanin M. Yu., Artamonova E. V., Barsukov Yu. A., et al. Рractical recommendations for the drug treatment of rectal cancer. doi: 10.18027 / 2224-5057-2020-10-3s2-23][2. Guidelines of the US National Cancer Network (NCCN) in the field of oncology based on clinical practice (NCCN Guidelines "Rectal Cancer", 2019. – 111 с.][3. Modern screening methods for asymptomatic colorectal cancer and precancerous diseases of the colon. - Bulletin of Surgery of Kazakhstan. - No. 1. - Shelygin Yu. A. и соавт. – 2010. – С. 32-34.][4. Zaletaev D.V. Strelnikov V.V. T.V. Kekeeva et al. Methylation anomalies in the processes of carcinogenesis: the search for new genes, the development of methods and systems of DNA markers for the diagnosis of cancer. Volume 9, No. 3 (2011) DOI: 10.17816ecogen9327-32.][5. Sabarimurugan S, Kumarasamy C, Madurantakam Royam M. et al. Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies. Medicine (Baltimore). 2019 Mar;98(12):e14570. doi: 10.1097/MD.0000000000014570. PMID: 30896613; PMCID: PMC6709282.][6. Nguyen T, Diaz D, Tagett R, Draghici S. Overcoming the matched-sample bottleneck: an orthogonal approach to integrate omic data. Sci Rep. 2016 Jul 12;6:29251. doi: 10.1038/srep29251. PMID: 27403564; PMCID: PMC4941544][7. Lam K, Pan K, Linnekamp JF, et al. DNA methylation based biomarkers in colorectal cancer: A systematic review. Biochim Biophys Acta. 2016 Aug;1866(1):106-20. doi: 10.1016/j.bbcan.2016.07.001. Epub 2016 Jul 3. PMID: 27385266.][8. Shao Y, Gu W, Ning Z, et al. Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets. Cell Physiol Biochem. 2017;41(4):1468-1480. doi: 10.1159/000470649. Epub 2017 Mar 24. PMID: 28351024.][9. Peng Z, Zhu W, Dai J, Ju F. MicroRNA-200 as potential diagnostic markers for colorectal cancer: meta-analysis and experimental validation. Cell Mol Biol (Noisy-le-grand). 2018 May 15; 64(6):77-85. PMID: 29808805.][10. Yau TO, Tang CM, Harriss EK, et al. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: A meta-analysis. Sci Rep. 2019 Jul 1;9(1):9491. doi: 10.1038/s41598-019-45570-9. PMID: 31263200; PMCID: PMC6603164.][11.Wang YH, Ji J, Weng H, et al. MiR-139 in digestive system tumor diagnosis and detection: Bioinformatics and meta-analysis. Clin Chim Acta. 2018 Oct;485:33-41. doi: 10.1016/j.cca.2018.06.006. Epub 2018 Jun 5. PMID: 29883634.][12. Gu X, Jin R, Mao X, et al. Prognostic value of miRNA-181a/b in colorectal cancer: a meta-analysis. Biomark Med. 2018 Mar;12(3):299-308. doi: 10.2217/bmm-2016-0222. Epub 2017 Aug 25. PMID: 28841043.][13. Zhang Q, Wang Q, Sun W, et al. Change of Circulating and Tissue-Based miR-20a in Human Cancers and Associated Prognostic Implication: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018 Nov 25;2018:6124927. doi: 10.1155/2018/6124927. PMID: 30596096; PMCID: PMC6286746.][14. Huang Q, Song Q, Zhong W, et al. MicroRNA-10b and the clinical outcomes of various cancers: A systematic review and meta-analysis. Clin Chim Acta. 2017 Nov;474:14-22. doi: 10.1016/j.cca.2017.08.034. Epub 2017 Aug 31. PMID: 28864233.][15. Li C, Yan G, Yin L, et al. Prognostic roles of microRNA 143 and microRNA 145 in colorectal cancer: A meta-analysis. Int J Biol Markers. 2019 Mar;34(1):6-14. doi: 10.1177/1724600818807492. Epub 2019 Mar 10. PMID: 30854930.][16. Guraya S. Prognostic significance of circulating microRNA-21 expression in esophageal, pancreatic and colorectal cancers; a systematic review and meta-analysis. Int J Surg. 2018 Dec; 60:41-47. doi: 10.1016/j.ijsu.2018.10.030. Epub 2018 Oct 15. PMID: 30336280.][17. Sur D, Burz C, Sabarimurugan S, Irimie A. Diagnostic and Prognostic Significance of MiR-150 in Colorectal Cancer: A Systematic Review and Meta-Analysis. J Pers Med. 2020 Aug 24;10(3):99. doi: 10.3390/jpm10030099. PMID: 32847098; PMCID: PMC7563128.][18. Carter JV, Galbraith NJ, Yang D, et al. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2017 Mar 14;116(6):762-774. doi: 10.1038/bjc.2017.12. Epub 2017 Feb 2. PMID: 28152545; PMCID: PMC5355921.][19. Liu T, Yin L, Yan G, et al. A meta-analysis of microRNA-17 as a potential biomarker in diagnosis of colorectal cancer. Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):86-93. PMID: 29808806.][20. Durso DF, Bacalini MG, do Valle ÍF, et al. Aberrant methylation patterns in colorectal cancer: a meta-analysis. Oncotarget. 2017 Feb 21;8(8):12820-12830. doi: 10.18632/oncotarget.14590. PMID: 28086223; PMCID: PMC5355058.][21. Advani SM, Advani P, DeSantis SM, et al. Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. Transl Oncol. 2018 Oct;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. Epub 2018 Jul 30. PMID: 30071442; PMCID: PMC6080640.][22. Liu R, Su X, Long Y, et al. A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. Mutat Res. 2019 Jan-Mar;779:45-57. doi: 10.1016/j.mrrev.2019.01.003. Epub 2019 Jan 16. PMID: 31097151.][23. Yu J, Xie Y, Li M, et al. Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis. Oncol Lett. 2019 Oct;18(4):3481-3492. doi: 10.3892/ol.2019.10709. Epub 2019 Aug 2. PMID: 31516566; PMCID: PMC6733008.][24. Mojtabanezhad Shariatpanahi A, Yassi M, Nouraie M, et al. The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis. PLoS One. 2018 Jul 19;13 (7):e0200735. doi: 10.1371/journal.pone.0200735. PMID: 30024936; PMCID: PMC6053185.][25. Liang TJ, Wang HX, Zheng YY, Cao YQ, Wu X, Zhou X, Dong SX. APC hypermethylation for early diagnosis of colorectal cancer: a meta-analysis and literature review. Oncotarget. 2017 Jul 11;8(28):46468-46479. doi: 10.18632/oncotarget.17576. PMID: 28515349; PMCID: PMC5542282.][26. Zhou Z, Zhang H, Lei Y. Diagnostic value of secreted frizzled-related protein 2 gene promoter hypermethylation in stool for colorectal cancer: A meta-analysis. J Cancer Res Ther. 2016 Oct;12(Supplement):30-33. doi: 10.4103/0973-1482.191625. PMID: 27721248.][27. Ye M, Huang T, Li J, et al. Role of CDH13 promoter methylation in the carcinogenesis, progression, and prognosis of colorectal cancer: A systematic meta-analysis under PRISMA guidelines. Medicine (Baltimore). 2017 Jan;96(4):e5956. doi: 10.1097/MD.0000000000005956. PMID: 28121942; PMCID: PMC5287966.][28. Shi B, Chu J, Gao Q, Tian T. Promoter methylation of human mutL homolog 1 and colorectal cancer risk: A meta-analysis. J Cancer Res Ther. 2018;14(4):851-855. doi: 10.4103/0973-1482.172587. PMID: 29970664.][29. Hu H, Zhou C, Li B, et al. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis. Pathol Res Pract. 2018 Oct;214(10):1572-1578. doi: 10.1016/j.prp.2018.07.031. Epub 2018 Jul 27. PMID: 30082160.][30. Zhang HF, Lu YW, Xie ZR, Wang KH. Relationship Between Human mutL Homolog 1 (hMLH1) Hypermethylation and Colorectal Cancer: A Meta-Analysis. Med Sci Monit. 2017 Jun 21;23:3026-3038. doi: 10.12659/msm.895643. PMID: 28635682; PMCID: PMC6179171.][31. Raut J.R, Guan Z, Schrotz-King P, Brenner H. Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review. Clin Epigenetics. 2020 Aug 10;12(1):122. doi: 10.1186/s13148-020-00904-7. PMID: 32778176; PMCID: PMC7418412.][32. Nian J, Sun X, Ming S, et al. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2017 Jan 19;8(1):e216. doi: 10.1038/ctg.2016.66. PMID: 28102859; PMCID: PMC5288600.][33. Bach S, Sluiter NR, Beagan JJ, et al. Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. JNCI Cancer Spectr. 2019 Jun 19;3(3):pkz042. doi: 10.1093/jncics/pkz042. PMID: 32328554; PMCID: PMC7050033.][34. Li B, Gan A, Chen X, et al. Diagnostic Performance of DNA Hypermethylation Markers in Peripheral Blood for the Detection of Colorectal Cancer: A Meta-Analysis and Systematic Review. PLoS One. 2016 May 9;11(5):e0155095. doi: 10.1371/journal.pone.0155095. PMID: 27158984; PMCID: PMC4861294.][35. Altobelli E, Angeletti PM, Latella G. Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2016 Oct 8;7(14):1984-2004. doi: 10.7150/jca.16244. PMID: 27877214; PMCID: PMC5118662.][36. Ye D, Jiang D, Li Y, et al. The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis. Int J Clin Oncol. 2017 Aug;22(4):749-757. doi: 10.1007/s10147-017-1106-1. Epub 2017 Mar 25. PMID: 28343299.][37. Rasmussen SL, Krarup HB, Sunesen KG, et al. Thorlacius-Ussing O. Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review. Colorectal Dis. 2016 Jun;18(6):549-61. doi: 10.1111/codi.13336. PMID: 26998585.][38. Iannone A, Losurdo G, Pricci M, et al. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis. J Gastrointest Cancer. 2016 Jun;47(2):143-51. doi: 10.1007/s12029-016-9810-z. PMID: 26922358.]